You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states

Article info

Article menu

Download PDFPDF

Treating Idiopathic Pulmonary Fibrosis
P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states
Free

Authors

Citation

Maher T, Noth I, Allinger A, et al
P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states
Thorax 2016;71:A175.

Publication history

  • First published November 15, 2016.
Online issue publication 
September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions